📌 Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior C

Elisabetta Bonzano MD, PhD· @to_be_elizabeth · X·2026-10-24 17:13· 1 day agoScore70

Body

📌 Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
@KalinskyKevin
#ESMO26 🇪🇸 @OncoAlert #OncoAlertAF

108 views · 4 likes · 3 reposts · 0 replies

Conference abstracts

1ROmatched by Rapid oral 1: Breast cancer, advanced stage

Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy

https://esmocongress.esmo.org

Source: Elisabetta Bonzano MD, PhD · x.com